Zhao X, Birchall JC, Coulman SA, Tatovic D, Singh RK, Wen L, Wong FS, Dayan CM, Hanna SJ. Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes. J Control Release. 2016; 223:178–187.
Vojislav C, Natasa R, Milica P, Slobodan A, Radivoj K, Danijela R, Sasa R. Incidence trend of type 1 diabetes mellitus in Serbia. BMC Endocr Disord. 2020; 20(1):34.
Roglic G. WHO global report on diabetes: a summary. Int J Noncommun Dis. 2016; 1(1):3.
Desai S, Deshmukh A. Mapping of type 1 diabetes mellitus. Curr Diabetes Rev. 2020; 16(5):438–441.
Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010; 464(7293):1293–1300.
Roep BO. The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia. 2003; 46(3):305–321.
Bach J-F, Chatenoud L. The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes. Cold Spring Harb Perspect Med. 2012; 2(2):a007799.
Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021; 17(3):150–161.
Kobos E, Imiela J. Factors affecting the level of burden of caregivers of children with type 1 diabetes. Appl Nurs Res. 2015; 28(2):142–149.
Commissariat PV, Harrington KR, Whitehouse AL, Miller KM, Hilliard ME, Van Name M, DeSalvo DJ, Tamborlane WV, Anderson BJ, DiMeglio LA, Laffel LM. “I’m essentially his pancreas”: parent perceptions of diabetes burden and opportunities to reduce burden in the care of children < 8 years old with type 1 diabetes. Pediatr Diabetes. 2020;21(2):377–83.
Al-Mutairi HF, Mohsen AM, Al-Mazidi ZM. Genetics of type I diabetes. Kuwait Med J. 2007; 39:107–115.
Acharjee S, Ghosh B, Al-Dhubiab BE, Nair AB. Understanding type 1 diabetes: etiology and models. Can J Diabetes. 2013; 37(4):269–276.
van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011;91(1):79–118.
Tosur M, Redondo MJ, Lyons SK. Adjuvant pharmacotherapies to insulin for the treatment of type 1 diabetes. Curr Diab Rep. 2018; 18(10):79.
Waldron-Lynch F, Herold KC. Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nat Rev Drug Discov. 2011; 10(6):439–452.
Tarbell KV, Petit L, Zuo X, Toy P, Luo X, Mqadmi A, Yang H, Suthanthiran M, Mojsov S, Steinman RM. Dendritic cell-expanded, islet-specific CD4 + CD25 + CD62L + regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med. 2007; 204(1):191–201.
Tai N, Yasuda H, Xiang Y, Zhang L, Rodriguez-Pinto D, Yokono K, Sherwin R, Wong FS, Nagata M, Wen L. IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clin Immunol. 2011; 139(3):336–349.
Ziegler A-G, Bonifacio E. Shortening the paths to type 1 diabetes mellitus prevention. Nat Rev Endocrinol. 2021; 17(2):73–74.
Rosenzwajg M, Salet R, Lorenzon R, Tchitchek N, Roux A, Bernard C, Carel J-C, Storey C, Polak M, Beltrand J, et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia. 2020; 63(9):1808–1821.
Nepom GT, Ehlers M, Mandrup-Poulsen T. Anti-cytokine therapies in T1D: Concepts and strategies. Clin Immunol. 2013; 149(3):279–285.
Pihl M, Barcenilla H, Axelsson S, Chéramy M, Åkerman L, Johansson I, Ludvigsson J, Casas R. GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients. Clin Immunol. 2017; 176:114–121.
Roep BO, Wheeler DCS, Peakman M. Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine. Lancet Diabetes Endocrinol. 2019; 7(1):65–74.
Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M. The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019; 7(1):52–64.
Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science. 2002; 296(5567):490–494.
Bach J-F. The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. Nat Rev Immunol. 2018; 18(2):105–120.
Saunders KA, Raine T, Cooke A, Lawrence CE. Inhibition of autoimmune type 1 diabetes by gastrointestinal helminth infection. Infect Immun. 2007; 75(1):397–407.
Lund ME, O’Brien BA, Hutchinson AT, Robinson MW, Simpson AM, Dalton JP, Donnelly S. Secreted proteins from the helminth Fasciola hepatica inhibit the initiation of autoreactive T cell responses and prevent diabetes in the NOD mouse. PLoS One. 2014; 9(1):e86289.
Berbudi A, Ajendra J, Wardani APF, Hoerauf A, Hübner MP. Parasitic helminths and their beneficial impact on type 1 and type 2 diabetes. Diabetes Metab Res Rev. 2016; 32(3):238–250.
Espinoza-Jiménez A, De Haro R, Terrazas LI. Antigens control experimental type 1 diabetes by inducing alternatively activated macrophages. Mediators Inflamm. 2017;2017:8074329.
Tang C-L, Zou J-N, Zhang R-H, Liu Z-M, Mao C-L. Helminths protect against type 1 diabetes: effects and mechanisms. Parasitol Res. 2019; 118(4):1087–1094.
Araújo MI, Hoppe BS, Medeiros M, Carvalho EM. Schistosoma mansoni infection modulates the immune response against allergic and auto-immune diseases. Mem Inst Oswaldo Cruz. 2004;99(5 Suppl 1):27–32.
Osada Y, Kanazawa T. Parasitic helminths: new weapons against immunological disorders. J Biomed Biotechnol. 2010;2010743758.
Kriegel MA, Sefik E, Hill JA, Wu H-J, Benoist C, Mathis D. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2011; 108(28):11548–11553.
Lau K, Benitez P, Ardissone A, Wilson TD, Collins EL, Lorca G, Li N, Sankar D, Wasserfall C, Neu J, et al. Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6.2-mediated Th17 bias. J Immunol. 2011; 186(6):3538–3546.
Yan K, Wang B, Zhou H, Luo Q, Shen J, Xu Y, Zhong Z. Amelioration of type 1 diabetes by recombinant fructose-1,6-bisphosphate aldolase and cystatin derived from Schistosoma japonicum in a murine model. Parasitol Res. 2020;119(1):203–14.
Hung J-T, Liao J-H, Lin Y-C, Chang H-Y, Wu S-F, Chang T-H, Kung JT, Hsieh S-L, McDevitt H, Sytwu H-K. Immunopathogenic role of TH1 cells in autoimmune diabetes: evidence from a T1 and T2 doubly transgenic non-obese diabetic mouse model. J Autoimmun. 2005; 25(3):181–192.
Zaccone P, Burton OT, Gibbs S, Miller N, Jones FM, Dunne DW, Cooke A. Immune modulation by Schistosoma mansoni antigens in NOD mice: effects on both innate and adaptive immune systems. J Biomed Biotechnol. 2010;2010:795210.
Duan Q, Xiong L, Liao C, Liu Z, Xiao Y, Huang R, Tan T, Ouyang Y, Cai J, Xiao M, et al. Population based and animal study on the effects of Schistosoma japonicum infection in the regulation of host glucose homeostasis. Acta Trop. 2018; 180:33–41.
Chen W, Wainer J, Ryoo SW, Qi X, Chang R, Li J, Lee SH, Min S, Wentworth A, Collins JE, et al. Dynamic omnidirectional adhesive microneedle system for oral macromolecular drug delivery. Sci Adv. 2022; 8(1):eabk1792.
Chen W, Wang Z, Wang L, Chen X. Smart chemical engineering-based lightweight and miniaturized attachable systems for advanced drug delivery and diagnostics. Adv Mater. 2022; 34(6):e2106701.
Chen W, Cai B, Geng Z, Chen F, Wang Z, Wang L, Chen X. Reducing false negatives in COVID-19 testing by using microneedle-based oropharyngeal swabs. Matter. 2020; 3(5):1589–1600.
Cai B, Gong Y, Wang Z, Wang L, Chen W. Microneedle arrays integrated with living organisms for smart biomedical applications. Theranostics. 2021; 11(20):10012–10029.
Chen W, Tian R, Xu C, Yung BC, Wang G, Liu Y, Ni Q, Zhang F, Zhou Z, Wang J, et al. Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy. Nat Commun. 2017; 8(1):1777.
Kim Y-C, Park J-H, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012; 64(14):1547–1568.
Haq MI, Smith E, John DN, Kalavala M, Edwards C, Anstey A, Morrissey A, Birchall JC. Clinical administration of microneedles: skin puncture, pain and sensation. Biomed Microdevices. 2009; 11(1):35–47.
Zhang Y, Yu J, Kahkoska AR, Wang J, Buse JB, Gu Z. Advances in transdermal insulin delivery. Adv Drug Deliv Rev. 2019; 139:51–70.
Wang P, Wang Y, Yi Y, Gong Y, Ji H, Gan Y, Xie F, Fan J, Wang X. MXenes-integrated microneedle combined with asiaticoside to penetrate the cuticle for treatment of diabetic foot ulcer. J Nanobiotechnology. 2022; 20(1):259.
Demuth PC, Garcia-Beltran WF, Ai-Ling ML, Hammond PT, Irvine DJ. Composite dissolving microneedles for coordinated control of antigen and adjuvant delivery kinetics in transcutaneous vaccination. Adv Funct Mater. 2013; 23(2):161–172.
Amani H, Shahbazi M-A, D’Amico C, Fontana F, Abbaszadeh S, Santos HA. Microneedles for painless transdermal immunotherapeutic applications. J Control Release. 2021; 330:185–217.
Park J, Kim Y-C. Topical delivery of 5-fluorouracil-loaded carboxymethyl chitosan nanoparticles using microneedles for keloid treatment. Drug Deliv Transl Res. 2021; 11(1):205–213.
Capanema NSV, Mansur AAP, de Jesus AC, Carvalho SM, de Oliveira LC, Mansur HS. Superabsorbent crosslinked carboxymethyl cellulose-PEG hydrogels for potential wound dressing applications. Int J Biol Macromol. 2018; 106:1218–1234.
Kim JD, Kim M, Yang H, Lee K, Jung H. Droplet-born air blowing: novel dissolving microneedle fabrication. J Control Release. 2013; 170(3):430–436.
Candido RRF, Favero V, Duke M, Karl S, Gutiérrez L, Woodward RC, Graeff-Teixeira C, Jones MK, St Pierre TG. The affinity of magnetic microspheres for Schistosoma eggs. Int J Parasitol. 2015; 45(1):43–50.
Karl S, Gutiérrez L, Lucyk-Maurer R, Kerr R, Candido RRF, Toh SQ, Saunders M, Shaw JA, Suvorova A, Hofmann A, et al. The iron distribution and magnetic properties of schistosome eggshells: implications for improved diagnostics. PLoS Negl Trop Dis. 2013; 7(5):e2219.
Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989; 299(6710):1259–1260.
Weintrob N, Sprecher E, Israel S, Pinhas-Hamiel O, Kwon OJ, Bloch K, Abramov N, Arbel A, Josefsberg Z, Brautbar C, Vardi P. Type 1 diabetes environmental factors and correspondence analysis of HLA class II genes in the Yemenite Jewish community in Israel. Diabetes Care. 2001; 24(4):650–653.
Elliott DE, Weinstock JV. Helminth-host immunological interactions: prevention and control of immune-mediated diseases. Ann N Y Acad Sci. 2012; 1247:83–96.
Du L, Tang H, Ma Z, Xu J, Gao W, Chen J, Gan W, Zhang Z, Yu X, Zhou X, Hu X. The protective effect of the recombinant 53-kDa protein of Trichinella spiralis on experimental colitis in mice. Dig Dis Sci. 2011; 56(10):2810–2817.
Weinstock JV, Elliott DE. Translatability of helminth therapy in inflammatory bowel diseases. Int J Parasitol. 2013; 43(3–4):245–251.
Leonardi I, Gerstgrasser A, Schmidt TSB, Nicholls F, Tewes B, Greinwald R, von Mering C, Rogler G, Frey-Wagner I. Preventive Trichuris suis ova (TSO) treatment protects immunocompetent rabbits from DSS colitis but may be detrimental under conditions of immunosuppression. Sci Rep. 2017; 7(1):16500.
Kron MA, Metwali A, Vodanovic-Jankovic S, Elliott D. Nematode asparaginyl-tRNA synthetase resolves intestinal inflammation in mice with T-cell transfer colitis. Clin Vaccine Immunol. 2013; 20(2):276–281.
Navarro S, Pickering DA, Ferreira IB, Jones L, Ryan S, Troy S, Leech A, Hotez PJ, Zhan B, Laha T, et al. Hookworm recombinant protein promotes regulatory T cell responses that suppress experimental asthma. Sci Transl Med. 2016; 8(362):362ra143.
Hirahara K, Vahedi G, Ghoreschi K, Yang X-P, Nakayamada S, Kanno Y, O’Shea JJ, Laurence A. Helper T-cell differentiation and plasticity: insights from epigenetics. Immunology. 2011; 134(3):235–245.
Martínez-Méndez D, Villarreal C, Mendoza L, Huerta L. An integrative network modeling approach to T CD4 cell activation. Front Physiol. 2020; 11:380.
McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011; 186(7):3918–3926.
McSorley HJ, Maizels RM. Helminth infections and host immune regulation. Clin Microbiol Rev. 2012; 25(4):585–608.
Fairfax K, Nascimento M, Huang SC-C, Everts B, Pearce EJ. Th2 responses in schistosomiasis. Semin Immunopathol. 2012; 34(6):863–871.
Cooke A, Tonks P, Jones FM, O’Shea H, Hutchings P, Fulford AJ, Dunne DW. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice. Parasite Immunol. 1999;21(4):169–76.
Zaccone P, Burton O, Miller N, Jones FM, Dunne DW, Cooke A. Schistosoma mansoni egg antigens induce Treg that participate in diabetes prevention in NOD mice. Eur J Immunol. 2009; 39(4):1098–1107.
Cleenewerk L, Garssen J, Hogenkamp A. Clinical use of antigens as novel immunotherapies for autoimmune disorders. Front Immunol. 2020; 11:1821.
Zaccone P, Fehérvári Z, Jones FM, Sidobre S, Kronenberg M, Dunne DW, Cooke A. Schistosoma mansoni antigens modulate the activity of the innate immune response and prevent onset of type 1 diabetes. Eur J Immunol. 2003; 33(5):1439–1449.
Zaccone P, Burton OT, Gibbs SE, Miller N, Jones FM, Schramm G, Haas H, Doenhoff MJ, Dunne DW, Cooke A. The S. mansoni glycoprotein ω-1 induces Foxp3 expression in NOD mouse CD4+ T cells. Eur J Immunol. 2011; 41(9):2709–2718.
Zou J, Liu W, Lei J, Mo H, Wang C, Yu G, Cheng Y, Li Y. Effect of chronic infection with Schistosoma japonicum on multiple low-dose streptozotocin induced diabetes mellitus in mice. J Pathog Biol. 2006;24(1):51–5.
Hams E, Aviello G, Fallon PG. The schistosoma granuloma: friend or foe? Front Immunol. 2013; 4:89.
Wang L, Yu Z, Wan S, Wu F, Chen W, Zhang B, Lin D, Liu J, Xie H, Sun X, Wu Z. Exosomes derived from dendritic cells treated with soluble egg antigen attenuate DSS-induced colitis. Front Pharmacol. 2017; 8:651.
Wang S, Xie Y, Yang X, Wang X, Yan K, Zhong Z, Wang X, Xu Y, Zhang Y, Liu F, Shen J. Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice. Parasit Vectors. 2016;9:6.
McCrudden MTC, McAlister E, Courtenay AJ, González-Vázquez P, Singh TRR, Donnelly RF. Microneedle applications in improving skin appearance. Exp Dermatol. 2015; 24(8):561–566.
Richter-Johnson J, Kumar P, Choonara YE, du Toit LC, Pillay V. Therapeutic applications and pharmacoeconomics of microneedle technology. Expert Rev Pharmacoecon Outcomes Res. 2018; 18(4):359–369.
Ohta N, Asahi H, Hosaka Y, Minai M, Ishii A. Regulation of the human T-cell response to Schistosoma japonicum egg antigen by concomitant cellular and humoral mechanisms in vitro. Parasitol Res. 1991;77(1):54–8.
Carson JP, Robinson MW, Hsieh MH, Cody J, Le L, You H, McManus DP, Gobert GN. A comparative proteomics analysis of the egg secretions of three major schistosome species. Mol Biochem Parasitol. 2020; 240:111322.
He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother. 2015; 11(2):477–488.
Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protocols Pharmacol. 2015;70(1):5–47.
Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 1976; 193(4251):415–417.
Kolb-Bachofen V, Epstein S, Kiesel U, Kolb H. Low-dose streptozocin-induced diabetes in mice. Electron microscopy reveals single-cell insulitis before diabetes onset. Diabetes. 1988; 37(1):21–27.
Paik SG, Fleischer N, Shin SI. Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoimmune processes. Proc Natl Acad Sci U S A. 1980; 77(10):6129–6133.
Herold KC, Montag AG, Fitch FW. Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozocin. Diabetes. 1987; 36(7):796–801.
Klinkhammer C, Popowa P, Gleichmann H. Specific immunity to streptozocin. Cellular requirements for induction of lymphoproliferation. Diabetes. 1988; 37(1):74–80.
Klinkhammer C, Dohle C, Gleichmann H. T cell-dependent class II major histocompatibility complex antigen expression in vivo induced by the diabetogen streptozotocin. Immunobiology. 1989;180:1.
Cockfield SM, Ramassar V, Urmson J, Halloran PF. Multiple low dose streptozotocin induces systemic MHC expression in mice by triggering T cells to release IFN-gamma. J Immunol. 1989; 142(4):1120–1128.
Lukić ML, Stosić-Grujicić S, Shahin A. Effector mechanisms in low-dose streptozotocin-induced diabetes. Dev Immunol. 1998; 6(1–2):119–128.
Livanos AE, Greiner TU, Vangay P, Pathmasiri W, Stewart D, McRitchie S, Li H, Chung J, Sohn J, Kim S, et al. Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice. Nat Microbiol. 2016; 1(11):16140.
